Sustained All Round Leadership
Total Page:16
File Type:pdf, Size:1020Kb
SUSTAINED ALL ROUND LEADERSHIP Continued Outstanding Clinical Performance Enhanced Patient Experience FY12 Consolidated Revenues up 20.8% at Rs.31, 475 million Consolidated EBITDA up 22.5% at Rs. 5,131 million Consolidated PAT up 19.3% at Rs. 2,194 million Board recommends a dividend of Rs. 4 per share Chennai, May 29, 2012: Apollo Hospitals Enterprise Ltd (AHEL), (BSE: 508869, NSE: INE437A01024), the Healthcare Pioneer and leading provider of quality clinical care reported its consolidated financial results according to Indian GAAP for the quarter and financial year ended March 31, 2012. The results reinforce Apollo’s leadership as the most valuable and trusted healthcare provider. The company crossed the Rs.30 Billion milestone posting consolidated annual revenues of Rs. 31.5 Billion with a growth of 20.8% Y‐on‐Y. Consolidated EBITDA was up 22.5% at Rs.5, 131 Million with PAT growing at 19.3% at Rs.2, 194 Million. Board recommends Dividend of Rs 4 per Share Commenting on the 2011‐12 performance, Dr. Prathap C Reddy, Chairman said, “Apollo Hospitals continues to demonstrate strong momentum and sustained leadership through the fourth quarter to close out a year of strong growth and profitability.” He added, “With our mission to give our customers the latest in treatment technologies, we have delivered clinical excellence on par with the world’s best benchmarks. The value of care is further enhanced by our acclaimed patient Care emphasis that has helped us to put in place the world’s busiest transplantation program and undertake effective initiatives such as Robotic Surgery, a minimally invasive surgery. The re‐ accreditation of our facilities at Chennai, Delhi, Bangalore and Dhaka by JCI and the NABH accreditation awarded to our hospitals in Ahmedabad, Noida and Secunderabad further underscore our rigor on standards. The team has once again delivered a robust growth, while improving profitability, which is truly a reflection of our business model.” The year ahead per Dr. Prathap C Reddy is one of “further impetus to our key pillars of Patient Care Excellence, Clinical Excellence, Value Excellence, and thought through expansions to bring the best of technical and clinical advances for the benefit of customers. We have also initiated significant transformation initiatives that would further set us of up to achieve balanced growth across all our Centers of Excellence, Geographies and Formats. ”Our emphasis on using Information Technology to transform Health Care is yielding results in process efficiency and enhanced connectivity with Doctors & patients. Financial Highlights ● Audited Standalone FY12 Performance (in comparison to FY11) ○ Revenues grew 20.1% to Rs. 28,001 million compared to Rs. 23,320 million in FY11. ○ EBITDA grew 23.0% to Rs. 4,644 million as against Rs. 3,775 million in FY11. The EBITDA margin improved by 40 basis points to 16.6%. ○ PAT was Rs. 2,310 million vs. Rs. 1,817 million in FY11, growth of 27.1%. ○ Diluted EPS of Rs. 16.86 per share in FY12 ○ The Boards of Directors has recommended a dividend of Rs. 4 per share. ● Audited Consolidated FY12 Performance ○ Revenues grew 20.8% to Rs.31,475 million compared to Rs. 26,054 million in FY11. ○ EBITDA grew 22.5% to Rs. 5,131 million as against Rs. 4,190 million in FY11. The EBITDA margin improved by 22 basis points to 16.3%. ○ PAT was Rs. 2,194 million vs. Rs. 1,839 million in FY11, a growth of 19.3%. ○ Diluted EPS of Rs. 16.01 per share in FY12 ● Audited Standalone Q4FY12 Performance (in comparison to Q4FY11) ○ Revenues grew 19.8% to Rs.7,446 million compared to Rs. 6,214 million in Q4FY11. ○ EBITDA grew 25.8% to Rs.1200 million as against Rs. 954 million in Q4FY11. ○ PAT was Rs. 593 million vs. Rs. 471 million in Q4FY11, growth of 26.0%. ○ Diluted EPS of Rs. 4.27 per share in Q4FY12 ● Audited Consolidated Q4FY12 Performance ○ Revenues grew 20.4% to Rs.8,572 million compared to Rs. 7,121 million in Q4FY11. ○ EBITDA grew 25.9% to Rs. 1,309 million as against Rs. 1,039 million in Q4FY11. ○ PAT was Rs. 515 million vs. Rs. 466 million in Q4FY11, growth of 10.4%. ○ Diluted EPS of Rs. 3.70 per share in Q4FY12 Clinical Highlights Apollo Transplant Institutes: (ATI) We completed 929 Solid organ transplants in a single calendar Year to be the first to reach this milestone and become the busiest program of its kind in the world. New transplant facilities started in Bhubaneshwar and Ludhiana while consolidating its programs in Bangalore and Hyderabad. Apollo Institute of Robotic Surgery: This was launched in Chennai in November 2011 and has successfully completed 55 complicated surgeries with robotic assistance. Expanding this reach in Cardiac, Head and Neck Surgeries. Radiation Therapy: Plans to introduce TrueBeam Stx , during the first quarter of FY13 in Bangalore . Considered as one of the world’s most advanced radiation therapy machine, the TrueBeam Stx is an advanced radiation therapy machine engineered to perform the most sophisticated radiation therapy and radio‐surgery procedures with pinpoint accuracy and ultra‐fine precision. It will enable faster, accurate tumor targeting in the treatment of challenging cancers throughout the body, including those in the brain, pancreas and liver. Cardiac Excellence: The Cardiac CoE has thus far completed over 120,000 surgeries, a global milestone. Clinical Benchmarks: Further enhancement of focus on our respected Global Clinical Excellence Benchmark program (ACE @25) that measures clinical outcome across 25 additional outcomes aligned to our Centers of Excellence. This augmented program is being run across our centers. Attached: Details to the announcement For further information, please contact: R Krishnakumar Mayank Vaswani Apollo Hospitals Enterprise Ltd. Citigate Dewe Rogerson [email protected] mayank@cdr‐india.com +91 44 2829 7840 +91 22 6645 1230 About Apollo Hospitals Enterprise Ltd. (AHEL) It was in 1983, that Dr. Prathap Reddy made a pioneering endeavour by launching India’s first corporate hospital ‐ Apollo Hospital in Chennai. Now, as Asia largest and most trusted healthcare group, its presence includes over 8,200 beds across 50 Hospitals, 1,364 Pharmacies, 100 primary care and diagnostic Clinics, 100 Telemedicine units across 9 countries, medical business process outsourcing services, Health Insurance services, Global Projects Consultancy, 15 colleges of Nursing and Hospital Management and a Research Foundation with a focus on global Clinical Trials, epidemiological studies, stem cell and genetic research. Disclaimer Some of the statements in this document that are not historical facts are forward looking statements. These forward‐looking statements include our financial and growth projections as well as statements concerning our plans, strategies, intentions and beliefs concerning our business and the markets in which we operate. These statements are based on information currently available to us, and we assume no obligation to update these statements as circumstances change. There are risks and uncertainties that could cause actual events to differ materially from these forward‐looking statements. These risks include, but are not limited to, the level of market demand for our services, the highly‐competitive market for the types of services that we offer, market conditions that could cause our customers to reduce their spending for our services, our ability to create, acquire and build new businesses and to grow our existing businesses, our ability to attract and retain qualified personnel, currency fluctuations and market conditions in India and elsewhere around the world, and other risks not specifically mentioned herein but those that are common to industry. Further, this document may make references to reports and publications available in the public domain. Apollo Hospitals Enterprise Ltd. makes no representation as to their accuracy or that the company subscribes to those views / findings. The Company on a quarterly basis adopts and publishes Standalone financial results as per the stock exchange listing agreement requirements. The consolidated financial results provided for the Quarter are unaudited and for information purposes only. Details to the announcement Key Achievements – 4 Pillars At Apollo, corporate success is anchored by 4 key pillars Clinical Excellence, Technological Excellence, Patient Care Excellence and Value Excellence. Apollo Hospitals’ believes in delivery of best patient care, employing best‐in‐class procedures and technologies with an eye on sustainable growth performance. ● Clinical Excellence: Apollo strives to maintain consistently higher rates of case success rates. ● Technological Excellence: Apollo relies on world–class, state‐of–the–art equipment, devices and procedures to consistently deliver superior clinical outcomes. ● Patient Care Excellence: Apollo is driven by patient well‐being. ● Value Excellence: Apollo balances performance goals with top‐notch healthcare service delivery which is affordable to the masses. Operating Highlights ● The ‘Join Hands Patient Safety Campaign’ was launched by Dr Prathap C Reddy, Ms Kiran Mazumdar Shaw (Chairperson & MD ‐ Biocon) and Sir Muer Gray (Chief Knowledge Officer ‐ NHS, UK). The campaign is one that calls organizations to come on a single platform, work together and share best practices with each other. It covers 1,88,007 Hospitals working towards one common mission ‐ Patient Safety. ● The First Edition of the International Congress on Patient Safety, Best Practices for Asia was held in Hyderabad during 21 – 22 April, 2011. ● The Department of Neurosurgery, Institute of Neurosciences, Apollo Hospitals at Bhubaneswar carried out two level cervical disc replacements by prosthetic Cervical disc for the first time in the state of Odisha and eastern part of India. The patient, aged 54 years, had an excellent Neurological recovery and was discharged in 3 days. ● During FY12, Apollo Hospitals at Dhaka, Bangalore, Delhi and Chennai were re‐accredited by the JCI while Apollo Hospitals at Ahmedabad, Noida and Secunderabad received NABH Certification. ● Apollo Hospitals ,Kolkata successfully treated a patient suffering from a liver tumour with a new radiotherapy technique called Stereotactic Body Radiation Therapy (SBRT).